argenx commenced a tender offer for Forte Biosciences this morning, valuing the clinical-stage dermatology company at approximately $120 million. The Amsterdam-based immunology specialist is acquiring all outstanding shares of Forte at $3.00 per share in cash, representing a 42% premium to Forte's previous closing price. The tender expires January 24, 2025, with argenx holding a 19.9% stake prior to the offer.
Forte brings FB-102, a Phase 2 asset targeting atopic dermatitis through a novel IL-12/23 inhibition mechanism. The molecule completed a 200-patient trial in moderate-to-severe AD patients in Q3 2024, with topline data showing 58% EASI-75 response at week 16 versus 31% placebo. argenx's existing portfolio centers on efgartigimod, an FcRn antagonist generating €487 million in 2024 revenue across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy indications. The Forte acquisition marks argenx's first dermatology entry and third clinical-stage bolt-on since 2022.
The timing reflects sector-wide pressure on clinical-stage dermatology firms. Forte's enterprise value contracted 67% from its January 2024 peak following slower-than-projected enrollment in a planned FB-102 psoriasis study. argenx's balance sheet held €2.1 billion in cash at September 30, providing acquisition capacity without equity dilution. The tender structure bypasses Forte's board, though major shareholders representing 34% of shares tendered support agreements. argenx plans to integrate FB-102 into its existing EU regulatory infrastructure, potentially compressing the timeline to a 2027 EU filing by 8-12 months versus Forte's standalone path.
This consolidation accelerates a pattern visible across immunology platforms. Companies with single approved FcRn or cytokine-blocking assets are acquiring earlier-stage programs to defend against 2027-2029 biosimilar erosion. argenx's efgartigimod faces potential Sandoz and Amgen biosimilars by late 2028 under current FDA timelines. Adding a differentiated IL-12/23 mechanism in a $8.4 billion atopic dermatitis market provides revenue diversification ahead of that cliff. The Forte deal also eliminates a potential competitor in the EU dermatology tender process, where health systems are consolidating rare immunology spend into fewer vendor relationships.
Allocators should monitor three developments through Q1 2025. First, whether the tender reaches the 90% threshold argenx requires to execute a short-form merger and delist Forte by February. Second, any competing bids from dermatology-focused acquirers, particularly those seeking IL-12/23 assets after AbbVie's Skyrizi dominance in psoriasis. Third, argenx's updated 2025 guidance, expected in the March earnings call, which will clarify FB-102 development spend and any revenue acceleration assumptions for efgartigimod in existing indications. The company has previously guided to positive operating cash flow by 2026; this acquisition likely extends that timeline by 2-3 quarters.
The tender closes before the February FDA advisory committee calendar is published, but the deal does not hinge on near-term regulatory events. argenx is buying optionality, not certainty.